CEO: Claire Mazumbdar, Ph.D., MBA

Visit Website

Bicara Therapeutics aims to bring first-in-class precision immunotherapies to people living with cancer, including those who have developed resistance to widely used first- and second-line therapies, for meaningful and durable benefit.

Bicara’s bifunctional molecules are designed to precisely target the tumor, so they do not damage or destroy healthy cells, thereby minimizing side effects. Effective targeted tumor delivery can mean that lower doses are required for anti-tumor effect, resulting in less toxicity to healthy tissues elsewhere in the body.